ATE219686T1 - Proteinartige adjuvantien - Google Patents

Proteinartige adjuvantien

Info

Publication number
ATE219686T1
ATE219686T1 AT95924122T AT95924122T ATE219686T1 AT E219686 T1 ATE219686 T1 AT E219686T1 AT 95924122 T AT95924122 T AT 95924122T AT 95924122 T AT95924122 T AT 95924122T AT E219686 T1 ATE219686 T1 AT E219686T1
Authority
AT
Austria
Prior art keywords
immune response
modulated immune
alum
genetically
antigen
Prior art date
Application number
AT95924122T
Other languages
English (en)
Inventor
Diane M Gajewczyk
Heather A Boux
Deleted
Michel H Klein
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22979642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219686(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE219686T1 publication Critical patent/ATE219686T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95924122T 1994-06-10 1995-06-08 Proteinartige adjuvantien ATE219686T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25822894A 1994-06-10 1994-06-10
PCT/CA1995/000341 WO1995034323A2 (en) 1994-06-10 1995-06-08 Proteinaceous adjuvants

Publications (1)

Publication Number Publication Date
ATE219686T1 true ATE219686T1 (de) 2002-07-15

Family

ID=22979642

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95924122T ATE219686T1 (de) 1994-06-10 1995-06-08 Proteinartige adjuvantien
AT01201610T ATE429928T1 (de) 1994-06-10 1995-06-08 Proteinartige adjuvantien

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01201610T ATE429928T1 (de) 1994-06-10 1995-06-08 Proteinartige adjuvantien

Country Status (10)

Country Link
US (2) US20030072774A1 (de)
EP (3) EP1149589B1 (de)
AT (2) ATE219686T1 (de)
AU (1) AU2876595A (de)
CA (1) CA2192454A1 (de)
DE (2) DE69527202T3 (de)
DK (2) DK1149589T3 (de)
ES (2) ES2325475T3 (de)
PT (2) PT1149589E (de)
WO (1) WO1995034323A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
DE69434000T3 (de) 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
GB9500788D0 (en) * 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
EP1486215A3 (de) * 1997-03-21 2006-04-12 Chiron Corporation Detoxifizierte Mutanten bakterieller ADP-ribosylierender Toxine als parenterale Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1123711B9 (de) * 1998-10-21 2009-08-12 The Kitasato Institute Attenuierte Toxine als Adjuvantien
NZ512980A (en) 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2002016440A2 (en) 2000-08-25 2002-02-28 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
EP1404368B1 (de) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutantenformen von cholera holotoxin als adjuvans
AU2002322380B2 (en) * 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
CA2642848C (en) 2006-03-03 2016-07-12 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
EP2164957B1 (de) 2007-05-23 2017-07-12 The UAB Research Foundation Enttoxifizierte neuraminidase aus pneumococcus und ihre verwendungen
ES2534671T3 (es) 2007-09-11 2015-04-27 University Of Guelph Inmunógenos polisacáridos de la Clostridium difficile
WO2009039125A1 (en) * 2007-09-17 2009-03-26 The Schepens Eye Research Institute, Inc. Use of ocular neuropeptides as immune adjuvants
US8210944B2 (en) * 2007-10-29 2012-07-03 Igt Gaming system having display device with changeable wheel
JP5070006B2 (ja) * 2007-11-02 2012-11-07 株式会社オハラ 結晶化ガラス
EP2376526A4 (de) 2008-12-24 2013-02-27 Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M Modifizierte streptococcus pneumoniae pneumolysin (ply)-polypeptide
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
KR101696986B1 (ko) * 2011-12-21 2017-01-17 바이오넷-아시아, 컴퍼니 리미티드 변형된 보르데텔라 페르투씨스 균주
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
CA2988165C (en) 2014-06-20 2023-08-01 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
HK1259325A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2144129B (en) * 1981-08-24 1985-10-09 Vilas V Likhite Antigens as immunostimulant adjuvants
WO1989001976A1 (en) * 1987-09-04 1989-03-09 Amgen Inc. Recombinant dna-derived bordetella toxin subunit analogs
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5244657A (en) * 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5358868A (en) * 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) * 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
AP8900132A0 (en) * 1988-07-22 1991-01-14 Smithkline Biolog Bordetella pertussis vaccine
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
DE69434000T3 (de) * 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US5932714A (en) * 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
JPH11121079A (ja) * 1997-10-20 1999-04-30 Yazaki Corp 圧接コネクタ及び圧接コネクタの組立方法
AU2001271268A1 (en) * 2000-05-19 2001-12-03 The Administrators Of The Tulane Educational Fund Hybrid lt-a/ct-b holotoxin for use as an adjuvant
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
ES2526822T3 (es) * 2002-01-31 2015-01-15 Andromeda Bio Tech Ltd. Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions

Also Published As

Publication number Publication date
DE69527202T3 (de) 2008-07-31
ES2325475T3 (es) 2009-09-07
AU2876595A (en) 1996-01-05
EP0764029A1 (de) 1997-03-26
EP0764029B1 (de) 2002-06-26
DE69527202T2 (de) 2002-12-05
EP1149588A1 (de) 2001-10-31
US20030072774A1 (en) 2003-04-17
ATE429928T1 (de) 2009-05-15
PT764029E (pt) 2002-10-31
CA2192454A1 (en) 1995-12-21
ES2179105T5 (es) 2008-06-16
WO1995034323A2 (en) 1995-12-21
PT1149589E (pt) 2009-07-28
DE69535943D1 (de) 2009-06-10
DK0764029T3 (da) 2002-10-21
ES2179105T3 (es) 2003-01-16
EP0764029B2 (de) 2008-03-26
EP1149589B1 (de) 2009-04-29
US7105161B1 (en) 2006-09-12
EP1149589A1 (de) 2001-10-31
DK0764029T4 (da) 2008-07-28
DK1149589T3 (da) 2009-08-17
DE69527202D1 (de) 2002-08-01
WO1995034323A3 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
ATE429928T1 (de) Proteinartige adjuvantien
NO930938L (no) Forbedrede vaksiner
EA200501070A1 (ru) Поливалентная вакцинная композиция
AU4188100A (en) Dry formulation for transcutaneous immunization
GB9419979D0 (en) Vaccine compositions
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
KR950701822A (ko) 간염B 표면 항원 및 다른 항원으로 구성된 조합 백신(Combined vaccines comprising hepatitis B surface antigen and other antines)
BR9710460A (pt) Composi-Æo imunolÄgica multi-valente e seu uso em vacinas
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
NO970993L (no) Mutant enterotoksin som er effektiv som en ikke-toksisk oral adjuvant
BR9510223A (pt) Adjuvante para vacinas utilização de um polissacarideo lipidico processo para preparar uma cacina em emulsão e vacina
WO2001068129A3 (de) Adjuvans für vakzinen
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
FI972054A0 (fi) Immunogeenisiä koostumuksia
ATE329615T1 (de) Borrelia burgdorferi bacterin
DK1223975T3 (da) Mukosale DTPa-vacciner
AU7960101A (en) Parenteral vaccine formulations and uses thereof
EP0591384A4 (de) Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1.
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0764029

Country of ref document: EP